J&J Trying To Back Out Of 77 Risperdal Deals, Plaintiffs Say

Law360, Philadelphia (November 12, 2013, 6:46 PM EST) -- A group of nearly 80 plaintiffs pursuing lawsuits against a Johnson & Johnson subsidiary in Pennsylvania state court over injuries they allegedly suffered from the antipsychotic drug Risperdal said last week that the company was attempting to renege on settlement deals agreed to in January.

The plaintiffs, who allege they were improperly prescribed the drug off-label after a major marketing push by J&J unit Janssen Pharmaceuticals Inc., said on Nov.5 that the company has refused to finalize settlements it agreed to in January in 77 cases pending as part of a mass tort program in the Philadelphia County Court of Common...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS